Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. - Wikidata - wikimedia - TriplyDB

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

http://www.wikidata.org/entity/Q35948528

about

Revolutionizing Alzheimer's disease and clinical trials through biomarkers A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers Suspected non-Alzheimer disease pathophysiology--concept and controversy The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Harmonized diagnostic criteria for Alzheimer's disease: recommendations Ushering in the study and treatment of preclinical Alzheimer disease Three dimensions of the amyloid hypothesis: time, space and 'wingmen'Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old.Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2 Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.Amyloid burden and neural function in people at risk for Alzheimer's Disease.Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology.The preclinical Alzheimer cognitive composite: measuring amyloid-related decline Early detection of Alzheimer's disease using PiB and FDG PET PART and SNAP.Molecular imaging of Alzheimer disease pathology The evolution of preclinical Alzheimer's disease: implications for prevention trials.Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.Emerging biomarkers in cognition.Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression Pittsburgh compound B retention and progression of cognitive status--a meta-analysis.Imaging biomarkers associated with cognitive decline: a review.Are AD-Typical Regions the Convergence Point of Multiple Pathologies?Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.Voxel Level Survival Analysis of Grey Matter Volume and Incident Mild Cognitive Impairment or Alzheimer's Disease A Summary Score for the Framingham Heart Study Neuropsychological Battery.Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease Absence of practice effects in preclinical Alzheimer's disease.Suspected non-AD pathology in mild cognitive impairment

P2860

Q26744882-9B93AFAF-5615-42E8-A451-A1B53A61234E Q26745508-37BFFE83-3168-4F68-88BE-3D6F111011B6 Q26771270-89A39057-A553-4CF5-BDBE-3A63ACB5F195 Q26830467-9145753E-EBC4-48CC-8715-E033AFF9E697 Q26995405-5D0D13C0-FBE5-461B-A596-F33BF67D1C38 Q27009157-B3E93268-5563-48EB-8ED4-313E6A3E0386 Q27014791-9F78678F-D0AD-45DA-9AD1-3B09255EA016 Q28082768-07CE11A3-0519-44A8-AC1A-72AEE1D432C2 Q28488143-201CD920-A5B3-4196-8767-17A224EF8BFF Q29620245-F29A05F2-9A05-4909-9163-646E8857C1F3 Q30303122-D9925444-1B80-4C8D-A5F0-E44693B2179F Q30981669-49F64793-3EEC-4B15-9F4A-081AA876DA8A Q33559175-2C9AC58E-F7FD-4082-B820-0B2B3E666000 Q33573761-2BDC21F4-F31B-446A-9A63-EE538AFAF9F6 Q33599047-00C92B94-928E-4A0C-96DA-6BC6EF99E733 Q33616244-24FD754B-34BA-4BC0-94EE-B10C8B5D67FC Q33672569-20A71F88-3738-4CE9-9009-04678511063C Q33740879-25268FEF-6497-4C6D-9006-F6BF5BC0177D Q34043786-3694C3E0-8055-41B0-9536-AF6E66957BF7 Q34422469-07ADEECA-C501-4FDE-AEDD-EE033CF5C082 Q34483878-2FC65396-2EC0-42F1-8AA7-E153507D2FA5 Q34507153-1C9AF75B-41B2-4EA9-A0AB-D65E0F52FCC9 Q34651135-97F2A17D-B0B5-4071-BD5B-E3C075724035 Q34849048-9E316D27-8FF5-4410-B943-97568BCB0E47 Q34940642-7939B465-0C1C-43A2-8DD7-0F299B018606 Q35008258-79689E91-92D9-4352-986E-C1AE438F2213 Q35073049-EDEDED05-30E4-48EF-B779-4F495C965F13 Q35106472-1027C5F2-AC2B-42C2-BD09-845E007A6FC8 Q35115487-EA151370-D910-4357-9D8A-3DB969551AC2 Q35185786-58AB190A-2DF9-4FC6-9A89-6176DFAB1617 Q35216192-53EEFB96-F2BC-497B-B0DB-BCA41D280F84 Q35776386-9572418E-4316-464B-B633-36E7C3628CD2 Q35838385-CBAEDD42-CD12-421A-B067-030F30BA4A96 Q35850701-FF1339B0-BF99-4F8C-916C-D2AD9C06E6D2 Q35889053-45856122-7FC8-4E51-99D6-EB2B357C415F Q35998525-C1958DFA-80C4-4ADD-94B7-5065085A47F9 Q36154820-94D8D766-0C49-4E61-BAD8-2F326C805DBC Q36252707-D49C71A5-0438-4555-82CC-E8DE1C9A6E76 Q36269046-42F076BA-B2CB-4DED-9583-7BB03BD92DD6 Q36271438-A535E065-B48E-45C8-B9AF-571C501E940E

P2860

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

http://www.wikidata.org/entity/Q35948528

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@ast

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@en

type

label

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@ast

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@en

prefLabel

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@ast

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@en

P1433

Q35948528-C073C80C-E02C-4B0D-80E3-C04395B942EA

P1476

Q35948528-F0744931-7114-4CC2-B620-2F0A0681D3FC

P2093

Q35948528-1ACB2A9B-3E57-4FC2-9246-92154A007613

Q35948528-1E235D82-871D-4DFC-B27B-684BF7DC8A11

Q35948528-2010A7F0-C4A6-4E7E-9482-7D5423D7C23D

Q35948528-5DFA667C-1796-4158-9FA1-CFCD19CBBB83

Q35948528-844F4EE7-4430-4803-8318-2849E3D52545

Q35948528-8D562ABF-DDBB-4E9A-8FD2-710C0ED4A99E

Q35948528-AC412998-8F48-4E8A-9656-7DC720F5EFAF

Q35948528-ACD87B9C-CD09-4E47-A3CC-A2C954F04E79

Q35948528-BD1F8F34-385C-4AFA-BD95-78F48EBE8A0A

Q35948528-E4019574-11B6-4003-B58A-8539A37FE0C4

P2860

Q35948528-068A71BA-12F6-484F-86BF-547ABBA74B09

Q35948528-0B05D9A0-589A-42D1-B93A-6A65BEF849E4

Q35948528-0D0AC6C8-4CEA-4B9B-B0ED-637A747100E4

Q35948528-11A83E08-5998-40D5-97A9-DFAB6A4FE7F9

Q35948528-11DBF5AC-B900-445C-8C81-EB0B7501DA0C

Q35948528-132589BA-C4A7-44D4-BC9F-10AC5499C7D8

Q35948528-373A62EA-1489-4AE2-BCC5-F442DE6D8DDF

Q35948528-38407BF4-C21B-43B4-AE47-8135470B066D

Q35948528-50D3659D-0EAD-4405-8F2F-1617C26EB05E

Q35948528-594202F3-677D-47EE-9B9D-6A0A2A51D90B

P304

Q35948528-70A10AF1-13FA-4F14-8E3E-A4C8D6839919

P31

Q35948528-F1C1187E-4023-4549-BCAC-17C1F8CA049F

P356

Q35948528-DB224CFF-ED29-4F53-8B21-9BEABB588739

P407

Q35948528-F8C9183C-2310-4EFC-8BAE-7B9E54E42790

P433

Q35948528-429454D5-AE3E-4708-BCC6-12E618D2EDDF

P478

Q35948528-B6439E9B-4117-490B-8A12-321472C28179

P50

Q35948528-4BA6727B-3867-4D6C-A491-FDB0E73A5C6B

Q35948528-F3AEF536-2F21-462C-98DF-CEA0FC49D00F

P577

Q35948528-030EAB3C-D3A6-4B2B-9908-2F921D27F14A

P5875

Q35948528-19109E38-233E-4B71-A0DF-210A15BFC368

P698

Q35948528-B01FD018-A269-4CCC-9EBD-F224FF1830A8

P921

Q35948528-4014A491-CBB5-4F7D-B5CB-B1666BD095E0

P932

Q35948528-05E1E646-7928-4392-9026-E85083E1B9C4

P356

WNL.0B013E3182563BBE

P1433

P1476

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

@en

P2093

B F Boeve

http://www.w3.org/2001/XMLSchema#string

D S Knopman

http://www.w3.org/2001/XMLSchema#string

H J Wiste

http://www.w3.org/2001/XMLSchema#string

J L Gunter

http://www.w3.org/2001/XMLSchema#string

M L Senjem

http://www.w3.org/2001/XMLSchema#string

P Vemuri

http://www.w3.org/2001/XMLSchema#string

R C Petersen

http://www.w3.org/2001/XMLSchema#string

R J Ivnik

http://www.w3.org/2001/XMLSchema#string

R O Roberts

http://www.w3.org/2001/XMLSchema#string

S D Weigand

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain

Mild cognitive impairment as a diagnostic entity

Measurement of MRI scanner performance with the ADNI phantom.

Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.

The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Amyloid imaging in mild cognitive impairment subtypes.

P304

1576-1582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3182563BBE

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224887553

http://www.w3.org/2001/XMLSchema#string

P698

22551733

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3348848

http://www.w3.org/2001/XMLSchema#string